Stepan Company filings document the regulatory record for a specialty and intermediate chemicals manufacturer whose common stock trades on the New York Stock Exchange under symbol SCL. Its 8-K filings report operating results, dividend declarations, material-event disclosures, capital-structure information and exit or disposal activities tied to manufacturing and efficiency initiatives.
Stepan proxy and annual-meeting filings cover director elections, advisory compensation votes, auditor ratification, executive compensation governance and benefit-plan matters. The filing record also includes disclosure on restructuring charges, asset write-downs, decommissioning costs and other governance or financial matters reported through current reports and proxy materials.
Stepan Company VP and GM Surfactants-INT Robin Joseph Weitkamp reported routine compensation-related equity activity involving restricted stock units (RSUs) and common stock.
On May 11, 2026, 90 RSUs were settled into 90 shares of common stock per the award terms. To cover tax obligations on the RSU vesting, 50 shares of common stock were withheld at a value of $52.58 per share, leaving 40 shares of common stock held directly after the transactions. The filing also shows 96.9 shares of common stock held indirectly through the ESOP II Trust.
Stepan Company vice president, general counsel and secretary Shawn G. Lisle reported equity compensation awards and a correction to a prior filing. On March 2, 2026, he received 6,440 stock appreciation rights with a conversion price of $50.06, 2,247 performance shares, and 4,495 restricted stock units, each tied to one share of common stock. A separate February 27, 2026 entry shows a grant of 25.544 shares of common stock at $52.51 per share. The amendment updates the previously reported stock appreciation right exercise price from $17.47 to $50.06; all other terms remain unchanged.
Stepan Co VP & CHRO Andrea Jean Barry reported equity-based compensation grants and a correction to a prior filing. On March 2, 2026, she received 6,440 stock appreciation rights with a conversion price of $50.06, 2,247 performance shares, and 4,495 restricted stock units, each tied to one share of common stock. The RSUs vest ratably over three years, while the performance shares vest if Stepan Company certifies that certain performance goals are achieved for the period ending December 31, 2028. She also acquired 16.464 shares of common stock on February 27, 2026 as a grant. This Form 4/A amends the original Form 4 only to correct the stock appreciation right conversion price to $50.06 from $17.47; all other terms of the reported transactions remain unchanged.
STEPAN CO executive Sean Thomas Moriarty, VP & GM Surfactants, reported multiple equity-based compensation awards. On March 2, 2026, he received 4,495 restricted stock units, 2,247 performance shares, and 6,440 stock appreciation rights with a $50.06 exercise price. On February 27, 2026, he also acquired 56.765 shares of common stock as an award. The filing shows 14,205.2335 common shares held directly and 4,478.351 shares held indirectly through an ESOP II trust as of that date. This Form 4/A amends a prior filing solely to correct the stock appreciation right exercise price from $17.47 to $50.06; all other terms remain unchanged.
STEPAN CO executive Richard Finn, V.P. and General Manager of Polymers, reported new equity compensation awards. He received a stock appreciation right covering 7,155 shares of common stock with a conversion price of $50.06 per share, expiring on March 3, 2036. He was also granted 2,497 performance shares and 4,994 restricted stock units, each representing the right to receive one share of common stock, with the performance shares tied to goals for a period ending December 31, 2028. The RSUs and certain awards vest ratably over three years starting on the grant date.
This amended Form 4 corrects the previously reported conversion price of the stock appreciation right from $17.47 to $50.06; all other terms of the transaction remain unchanged. Following these awards, Finn reports 241,395.915 shares of common stock held directly, along with additional indirect holdings through an ESOP trust, a personal trust, and family accounts.
STEPAN CO Vice President and Chief Financial Officer Ruben Dario Velasquez reported multiple equity-based awards and an administrative correction. On March 2, 2026, he received 8,586 Stock Appreciation Rights tied to common stock with a conversion/exercise price of $50.06 and expiration on March 3, 2036. He was also granted 2,996 performance shares, which vest upon certification that performance goals for the period ending December 31, 2028 are achieved, and 5,993 restricted stock units that vest ratably over three years beginning on the grant date. In a separate award dated February 27, 2026, he acquired 35.601 shares of common stock at $52.51 per share. This Form 4/A amends a prior filing solely to correct the Stock Appreciation Right conversion/exercise price to $50.06 from $17.47; no other terms of the reported transactions are changed.
STEPAN CO executive Robert Joseph Haire reported multiple equity awards and corrected prior pricing details. The filing shows grants on March 2, 2026 of 8,586 Stock Appreciation Rights tied to common stock at a conversion/exercise price of $50.06, 2,996 performance shares, and 5,993 restricted stock units.
He also acquired 56.765 shares of common stock at $52.51 per share, bringing direct common stock holdings to 2,538.765 shares, plus 90.269 shares held indirectly through an ESOP II Trust. This Form 4/A amends a prior report only to correct the Stock Appreciation Right exercise price from $17.47 to $50.06; all other aspects of the reported transaction remain unchanged.
STEPAN CO President & CEO Luis Rojo reported several equity compensation awards. On March 2, 2026, he received 57,241 stock appreciation rights with a conversion price of $50.06, 39,952 performance shares, and 19,976 restricted stock units, each tied to one share of common stock. On February 27, 2026, he was granted 56.765 shares of common stock at $52.51. The filing also corrects an earlier Form 4 by revising the SAR conversion price to $50.06 from $17.47 due to an administrative error.
STEPAN CO director F. Painter Corning received a stock award of 2,566 shares of Common Stock on May 8, 2026. The grant is recorded at a price of $52.61 per share and is classified as a grant, award, or other acquisition rather than an open-market purchase. Following this non-derivative equity award, Corning directly holds 4,999 shares of Stepan common stock. This reflects routine director compensation in equity form, not a discretionary market trade.
STEPAN F QUINN JR reported acquisition or exercise transactions in this Form 4 filing.
STEPAN CO director Quinn Stepan Jr. reported a stock award of 2,566 shares of common stock on May 8, 2026, received as a grant rather than an open-market purchase, at a reported price of $52.61 per share. After this award, his directly held common stock position stands at 143,007.262 shares.
The filing also updates a series of indirect holdings in various related entities and family accounts, showing post-transaction balances such as 160,000 shares held by a Family LLC and 87,500 shares held by Family Trust IV, among others. Several other indirect entries, including certain family trusts and plan-related positions, are shown with zero balances, reflecting current reported holdings rather than clear buy or sell activity.